A phase II study of pemetrexed and pembrolizumab in recurrent and/or metastatic salivary gland malignancies

Authors :: Katharine Andress Rowe Price
Nathan R. Foster
Harry E. Fuentes Bayne
Casey Fazer
Panayiotis Savvides
Yujie Zhao
Patrick Walsh McGarrah
Anna C. Cooper
Ashish V. Chintakuntlawar
Source :: Journal of Clinical Oncology. 40:TPS6111-TPS6111
Publication Year :: 2022
Publisher :: American Society of Clinical Oncology (ASCO), 2022.
Abstract: TPS6111 Background: Treatment options for recurrent and/or metastatic (R/M) salivary gland cancer (SGC) are limited with response rates to standard cytotoxic chemotherapy (CT) low at 10-30%, and responses to single-agent immune checkpoint inhibition (ICI)

Full Text Access

Tools